Le Lézard
Classified in: Health, Science and technology
Subject: Merger/Acquisition

Praesidian Capital Acquires Genetics Business


Praesidian Capital, a leading private investment firm, announced today that it acquired an integrated clinical and laboratory services company in the high-growth field of genetic medicine. The company is a leader in the prenatal and preconception field, and it also provides hereditary cancer risk assessments. This is Praesidian's first acquisition as an independent sponsor and will serve as a strong platform as Praesidian looks to expand the business across the country.

"The company's unique and scalable business model is ideally suited for the high-growth genetic testing industry," stated Jason Drattell, Praesidian Founder. "This acquisition provides an exciting foundation for Praesidian's independent sponsor platform."

Glenn Harrison, Praesidian Capital Partner said: "Genetic testing is now an integral part of patient care. We have some of the best clinicians in the industry and are eager to expand the company's service offerings and footprint while continuing to provide industry leading care."

"We are very excited about closing our first deal as an independent sponsor," noted Tom Duffy, Managing Director. "As we build our equity portfolio, we will be evaluating add-on acquisitions as well as subsequent platform deals."

About Praesidian Capital

Praesidian Capital is an innovative private investment firm focused on providing senior and subordinated debt along with growth capital to private lower middle market businesses in the United States, United Kingdom, Germany, and selectively in Northern Europe. Praesidian also recently launched a private equity strategy focused on control positions in lower middle market businesses. Based in New York with an office in London, Praesidian manages nearly $1 billion in committed capital. For more information, visit www.praesidian.com.

To discuss prospective investment opportunities please contact:

Glenn Harrison, Partner ? [email protected] (212) 520-2612

Tom Duffy, Managing Director ? [email protected] (212) 520-2617

Bill Johnston, Sr. Associate ? [email protected] (212) 520-2632


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: